Most recently acquired 2,499 shares in Jun 2024. Currently holds stock worth $1.04M. 3+ years at the helm of Nuvalent, Inc..
Compensation History
Annual executive compensation data for Michael L. Meyers, M.D., Ph.D., including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$0.00
Salary
$0.00
Bonus
$0.00
Other
$0.00
Salary
$0.00Board Justification
The compensation philosophy aims to attract and retain qualified executives, motivate them to achieve business goals, and reward them for performance, aligning their interests with those of stockholders.
Bonus
$0.00Board Justification
No bonus was reported for 2023.
Other Compensation
$0.00Board Justification
No other compensation was reported for 2023.
Restricted Stock
Board Justification
No vested stock was reported for 2023.
Performance Metrics
No specific performance metrics were reported for determining compensation in 2023.
Michael L. Meyers, M.D., Ph.D.
CEO of Nuvalent, Inc.
Education
M.D., Ph.D.
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
CEO of Nuvalent, Inc. for
3 years 2 months (Oct 2022 - Present)
Previous Experience
Former executive at various biotech companies
Other Nuvalent, Inc. CEOs
Holdings
Track Michael L. Meyers, M.D., Ph.D.'s stock holdings and portfolio value over time.
Insider Trading
Michael L. Meyers, M.D., Ph.D.'s recent stock transactions, purchases, and sales filed with the SEC.
2,499 shares
NUVL
Jun 12, 2024
Received
$7.73K
SNDX at $15.46/share
Apr 26, 2021
Purchase
3,500 shares
SNDX
Jul 6, 2020
Received
$5.41K
SNDX at $4.90/share
Mar 21, 2019
Purchase
$38.96
SNDX at $4.87/share
Mar 21, 2019
Purchase
$958.00
SNDX at $4.79/share
Oct 30, 2018
Purchase
Rivals
Compare Michael L. Meyers, M.D., Ph.D. with competitor CEOs and industry peers.